Latest Oncology News

IMpower010 Data Show OS Trend in Favor of Adjuvant Atezolizumab Vs BSC in PD-L1+ Resected NSCLC

August 8th 2022

Hayley Virgil

An overall survival trend in favor of adjuvant atezolizumab over best supportive care was observed in patients with stage II to IIIA resected non–small cell lung cancer with a PD-L1 tumor cell (TC) expression of at least 1%, with a clinically meaningful OS trend noted in those with a PD-L1 TC expression of 50% or higher.

Neoadjuvant Nivolumab Plus Chemo Improves Survival Vs Chemo Alone in Resectable Stage IIIA/B NSCLC

August 8th 2022

Hayley Virgil

The addition of nivolumab to chemotherapy provided progression-free survival and overall survival benefits compared with chemotherapy alone in patients with stage IIIA/B non–small cell lung cancer.

Pembrolizumab Plus Lenvatinib Elicits Positive Clinical Activity in Recurrent Pleural Mesothelioma

August 7th 2022

Jordyn Sava

The combination of pembrolizumab and lenvatinib generated promising clinical activity with a manageable safety profile in pretreated patients with malignant pleural mesothelioma.

Sotorasib Plus SHP2 Inhibition Elicits Promising Preliminary Activity in KRAS G12C–Mutated NSCLC

August 7th 2022

Caroline Seymour

The combination of sotorasib and the small molecule SHP2 inhibitor RMC-4630 led to an investigator-assessed objective response rate of 27% and 50% in pretreated and KRAS G12C inhibitor–naïve patients with non–small cell lung cancer, respectively.

VISION Trial Cohort C Data Confirm Robust Efficacy of Tepotinib in METex14-Altered NSCLC

August 7th 2022

Kristi Rosa

The robust efficacy achieved with tepotinib in patients with non–small cell lung cancer harboring MET exon 14 skipping alterations was independently confirmed in data from the primary analysis of cohort C of the phase 2 VISION trial.

Latest Oncology Videos

ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04

Management and Work-up of Patients for Salvage Therapy

Dr. Hong on the Significance of Larotrectinib in NTRK-Positive NSCLC

Measuring Ki-67 Levels to Inform HR+ Breast Cancer Treatment

Novel Immunotherapy Agent Tebentafusp for Treatment of Metastatic Uveal Melanoma

Frontline Treatment Strategies for Chronic GVHD

Novel Treatment Strategies for HER2-Low Breast Cancer

Improving the Early Identification of Chronic Graft Versus Host Disease

Establishing the Paradigm of HER2-Low Breast Cancer

Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer

Strategies for Supportive Care and Monitoring in Patients Who Have Received CAR T-Cell Therapy

Dr. Iams on the Evaluation of Sotorasib in KRAS G12C–Mutant Solid Tumors

Dr. Tilly on Pola-R-CHP in an Asia Subpopulation of Patients With DLBCL

Dr. Maude on Safety of Tisagenlecleucel in Pediatric B-ALL

The Evolution of Early-Stage HR+ Breast Cancer Management

Advancements on the Horizon in Mantle Cell Lymphoma

Strategies for Sequencing and Combining Therapies in MCL

CheckMate 9LA: Dual IO Therapy With Chemotherapy in Advanced NSCLC

Dual IO Therapy in Advanced NSCLC: Long-Term Followup From CheckMate 227

Dr. Leleu on the Future of Later-Line Therapy in Multiple Myeloma

Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study

Dr. Seedor on Treatment Sequencing in Metastatic Melanoma

Addressing Adverse Events With Bispecific Antibodies with Focus on CRS Management

All Oncology News

Positive Abemaciclib Data Emerge for Chinese Women With HR+ Breast Cancer

September 30th 2019

Onclive Team

A population of predominantly Chinese women with advanced hormone receptor–positive/HER2-negative breast cancer obtained significant benefits from treatment with the CDK4/6 inhibitor abemaciclib and endocrine therapy.

Atezolizumab/Chemo Improves PFS in Metastatic Urothelial Cancer

September 30th 2019

Gina Columbus

The first-line combination of atezolizumab (Tecentriq) and chemotherapy led to an improvement in median progression-free survival compared with placebo/chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.

ClarIDHy Ivosidenib Data Practice-Changing for Advanced Cholangiocarcinoma

September 30th 2019

Silas Inman

Treatment with ivosidenib reduced the risk of progression or death by 63% compared with placebo for pretreated patients with IDH1-mutant advanced cholangiocarcinoma.

Olaparib Doubles rPFS in Heavily Pretreated HRR+ mCRPC

September 30th 2019

Silas Inman

Olaparib improved radiographic progression-free survival compared with physician's choice of abiraterone acetate or enzalutamide in men with heavily pretreated metastatic castration-resistant prostate cancer with homologous recombination repair (HRR) gene alterations.

Larotrectinib Continues to Show High Efficacy, Low Toxicity in TRK Fusion-Positive Cancers

September 29th 2019

Onclive Team

The tumor-agnostic TRK inhibitor larotrectinib (Vitrakvi) demonstrated marked antitumor efficacy, including objective responses that often persisted for years, and a favorable safety profile.

Dr. Slamon on OS Results of the MONALEESA-3 Trial in HR+/HER2- Breast Cancer

September 29th 2019

Dennis J. Slamon, MD, PhD

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the overall survival results of the phase III MONALEESA-3 trial in hormone receptor-positive, HER2-negative breast cancer.

Dr. Gonzalez-Martin on the Results of the PRIMA Trial in Ovarian Cancer

September 29th 2019

Antonio Gonzalez-Martin, MD

Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the results of the phase III PRIMA trial in advanced ovarian cancer.

Selpercatinib Shows Strong ORR in Thyroid Cancer, FDA Submission Expected

September 29th 2019

Silas Inman

The highly selective RET inhibitor selpercatinib (formally LOXO-292) demonstrated robust objective response rates for patients with RET-mutant medullary thyroid cancer and in those with other RET fusion-positive thyroid cancer.

PD-L1 Assays Demonstrate

September 29th 2019

Wayne Kuznar

An exploratory biomarker substudy of Impassion130 demonstrated clinical activity of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) in a subgroup of patients with triple-negative breast cancer who had immune cell PD-L1 expression by the SP142 immunohistochemistry assay, regardless of the site of the tumor sample.

Abemaciclib/Fulvestrant Improves Survival in HR+ Advanced Breast Cancer

September 29th 2019

Gina Columbus

The addition of the CDK4/6 inhibitor abemaciclib (Verzenio) to fulvestrant (Faslodex) led to a median 9.4-month overall survival benefit compared with fulvestrant with placebo in patients with hormone receptor–positive, HER2-negative advanced breast cancer who progressed on prior endocrine therapy.

Atezolizumab Combo Confirmed as Frontline Standard in Advanced Small Cell Lung Cancer

September 29th 2019

Wayne Kuznar

With follow-up of nearly 2 years, the addition of atezolizumab to first-line carboplatin plus etoposide for the treatment of extensive stage small cell lung cancer continues to demonstrate improved overall survival compared with placebo plus CP/ET.

Abemaciclib Activity Extends to HR+/HER2+ Breast Cancer

September 29th 2019

Onclive Team

Adding abemaciclib (Verzenio) and endocrine therapy to trastuzumab (Herceptin) improved progression-free survival in advanced hormone receptor-positive, HER2-positive breast cancer versus trastuzumab and chemotherapy.

Ribociclib/Fulvestrant Combo Improves OS in Advanced HR+ Breast Cancer

September 29th 2019

Gina Columbus

The combination of ribociclib and fulvestrant led to an approximate 28% reduction in the risk of death compared with placebo and fulvestrant in postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Neoadjuvant Pembrolizumab Combo Prolongs pCR in Phase III TNBC Study

September 29th 2019

Silas Inman

Neoadjuvant treatment with the combination of pembrolizumab and chemotherapy extended pathological complete response rates by 13.6 percentage points compared with chemotherapy alone for patients with early triple-negative breast cancer.

Trilaciclib Delivers "Unexpected" Survival Boost in TNBC

September 29th 2019

Onclive Team

The investigational CDK4/6 inhibitor trilaciclib unexpectedly improved survival in metastatic triple-negative breast cancer despite failing to meet a safety-related primary endpoint.

See All News